Most pharmacies I've talked to have already added at least one clinical service beyond dispensing. Flu shots. Maybe minor-ailment prescribing, if the province allows it. Maybe a medication review program. The real question isn't whether to add a service — most owners already have. It's which one, if you had to pick where to put your next hour of clinical time, actually pays off.
I won't hand you invented dollar figures per shot or per consult — anyone who does that for a business they don't operate is guessing. What I can do is rank these services by their structure: how the money is allowed to flow, how many items land in a basket, whether demand repeats, and whether anyone nearby can copy you. Structure decides whether a service is a nice add-on or a real second line of business, and it's knowable without a single made-up number.
The four things that actually decide profitability
Here's the reasoning behind the ranking, so you can check it against your own province and pharmacy rather than take it on faith:
- Cash-pay vs. reimbursement-capped. A service billed to a provincial plan or an insurer gets whatever rate that payer sets, and that rate can be cut, frozen, or clawed back — you've lived this with dispensing fees already. A service the patient pays for directly is priced by you, not negotiated on your behalf by someone else.
- Consult fee plus product margin, vs. product margin alone. Dispensing is mostly the second kind: you're compensated for supplying something, with a thin fee attached. A service that bundles a paid clinical consultation with the products it recommends captures value twice from the same visit instead of once.
- Basket size — one item vs. several, one person vs. a family. A single flu shot is one line. A service that routinely produces multiple products per visit, or multiple visits per household, has a structurally bigger transaction without needing more foot traffic.
- Recurring demand and a competitive moat. Does the same patient need this again next year, and can the pharmacy across the street offer the identical thing tomorrow? A service that repeats and that requires a credential most competitors don't hold is worth more than one that's a one-time transaction anyone can copy.
Provincial scope of practice varies a lot — what an Ontario pharmacist can prescribe under minor-ailments rules isn't identical to Alberta, B.C., or Quebec, and that changes which services are even available to you. I'm ranking by economic structure, not asserting what's legal in your province; check your own college for that.
The ranking
7. Compounding
Real margin exists here, but it's capital- and equipment-intensive, closely regulated, and demand is thin unless you're near a niche referral source (palliative care, veterinary, hormone therapy). A specialty service for a specialty market — good if you already have it, not the first thing to build.
6. Compression stocking fitting
Cash-pay and product-margin-friendly, but a single-item, single-visit transaction with no natural repeat cycle beyond replacement wear, and any pharmacy with the fitting equipment can offer it. Useful complement, weak as a standalone growth line.
5. Smoking cessation counselling
Often structured as a multi-visit program, which is a point in its favour — recurring contact with the same patient. But the basket stays narrow (counselling plus one product category), and success by design reduces the patient's future need for you.
4. Medication reviews (MedsCheck-style programs)
Reimbursed, recurring by design, and genuinely useful for retention and adherence — but the fee is set by the payer, capped, and the review itself doesn't reliably generate a multi-item basket. A relationship play more than a profit-per-visit play.
3. Minor-ailment prescribing
Where your province allows it, this is a real structural upgrade: a paid consult plus a prescription plus, often, an OTC recommendation — two or three revenue lines from one visit, and it positions you as a clinician rather than a dispenser (a distinction covered in the respect gap). The ceiling is that most of these conditions resolve once; the patient doesn't need you again for the same complaint next month.
2. Routine and travel-adjacent immunizations (flu, shingles, etc.)
Cash-pay or reimbursed depending on the vaccine and province, genuinely recurring — flu is annual by definition — and low-friction to deliver. The structural cap is basket size: usually one shot, one visit, one line item. High volume, thin depth.
1. Travel medicine
This is where all four structural factors point the same direction at once, which is why it sits at the top rather than tied with something else:
- Cash-pay. Travel consultations and most travel vaccines are paid directly by the traveller, not adjudicated against a capped provincial or insurer fee schedule.
- Consult plus multi-item basket. A single consultation routinely produces several products at once — the consult fee, plus multiple vaccines depending on itinerary, plus antimalarial or traveller's-diarrhea prophylaxis prescriptions. Often it's a family booking one trip together, not one person.
- Demand that arrives pre-committed. A patient doesn't decide whether they feel like getting travel-vaccinated the way they might delay a med review. The trip is already booked, and the appointment has to happen before departure — about as close to guaranteed conversion as clinical retail gets.
- A licence most competitors don't hold. Yellow Fever vaccination specifically requires a designated centre licence, which most pharmacies in Canada don't have. That's a credential gap, not a marketing claim — we've mapped exactly how many pharmacies do hold it in our count of the 321 licensed Yellow Fever centres in Canada.
None of the other six services combine cash-pay pricing, a multi-item basket, pre-committed demand, and a licence moat in the same package. Some hit two of the four. Travel medicine is the only one that hits all four — a structural argument, not a promise about what any specific pharmacy will earn.
Why this isn't "just add travel medicine tomorrow"
Holding the Yellow Fever designation is necessary but not sufficient. The clinic still needs people who know the pharmacy offers it, on the week they're planning a trip. That's a demand-generation problem, not a licensing one — and it's the specific gap the pilot below is built to test.